India, Aug. 7 -- Editas Medicine, Inc. (EDIT) a clinical-stage gene editing company developing in vivo CRISPR gene-editing medicines for genetic diseases, reported a narrower net loss for the second quarter, primarily attributable to higher collaboration and other research and development revenues.
The company's lead candidate EDIT-401, is an investigational in vivo CRISPR gene-editing therapy being developed to treat hyperlipidemia and atherosclerotic cardiovascular disease by durably lowering LDL cholesterol.
For the second quarter ended June 30, 2026, net loss narrowed to $18.23 million, or $0.15 per share, from loss of $53.23 million, or $0.63 per share in the prior year.
Collaboration and other research and development revenue incre...